Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

NCT03085719 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Pembrolizumab
RADIATION: Radiation

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]